LRP2 and hereditary clear cell renal cell carcinoma: LRP2 has been proposed as a potential target for selective anti-cancer drug delivery, with studies showing that kidney-targeting multimodal micelles [25] and light-chain conjugated nanoparticles [26] can target renal cell carcinoma cells through their interaction with LRP2.